StockData
Neurocrine Biosciences Inc logo

Neurocrine Biosciences Inc (NBIX) stock

NBIXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 19/3018% below fair value
$146.10−0.28 (-0.19%)

Close on Oct 30, 2026Market cap $14.85BP/E 21.4Yield –

Earnings

Neurocrine Biosciences's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Oct 27, 2026
Q3 FY2026 · estimated, after the close
Revenue, Q2 FY2026
$959.00M
+39.5% on a year earlier
Non-GAAP Earnings Per Share – Diluted, Q2 FY2026
$2.85
$1.65 a year earlier
Latest guidance
Raised
Jul 30, 2026 · 6 items

Quarterly results

Revenue and earnings per share from each of Neurocrine Biosciences's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q3 FY2026ended Sep 30, 2026Oct 27, 2026Expected–––––
Q2 FY2026ended Jun 30, 2026Jul 30, 2026after the close$959.00M+39.5%$1.39$2.85Release
Q1 FY2026ended Mar 31, 2026May 5, 2026after the close$814.50M+42.2%$1.91$1.94Release
Q4 FY2025ended Dec 31, 2025Feb 11, 2026after the close$805.50M+28.3%$1.48$1.88Release
Q3 FY2025ended Sep 30, 2025Oct 28, 2025after the close––––Release
Q2 FY2025ended Jun 30, 2025Jul 30, 2025after the close$687.50M+16.5%$1.06$1.65Release
Q1 FY2025ended Mar 31, 2025May 5, 2025after the close$572.60M+11.1%$0.08$0.70Release
Q4 FY2024ended Dec 31, 2024Feb 6, 2025after the close$627.70M+21.8%$1.00$1.69Release
Q3 FY2024ended Sep 30, 2024Oct 30, 2024before the open$622.10M+24.7%$1.24$1.81Release
Q2 FY2024ended Jun 30, 2024Aug 1, 2024before the open$590.20M+30.4%$0.63$1.63Release
Q1 FY2024ended Mar 31, 2024May 1, 2024before the open$515.30M+22.6%$0.42$1.20Release
Q4 FY2023ended Dec 31, 2023Feb 7, 2024before the open$515.20M+25.0%$1.44$1.54Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Neurocrine Biosciences's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
GAAP Amortization of Acquired Intangible AssetsGAAPFY2026$85.00M – $90.00M–LoweredJul 30, 2026
GAAP and Non-GAAP IPR&DFY2026$20.00M$20.00MReaffirmedMay 5, 2026
GAAP R&DGAAPFY2026$1.28B – $1.33B–LoweredJul 30, 2026
GAAP R&D ExpenseGAAPFY2026$1.20B – $1.25B$1.20B – $1.25BLoweredMay 5, 2026
GAAP SG&AGAAPFY2026$1.58B – $1.60B–RaisedJul 30, 2026
GAAP SG&A ExpenseGAAPFY2026$1.38B – $1.40B$1.38B – $1.40BRaisedMay 5, 2026
IPR&DFY2026$23.00M–RaisedJul 30, 2026
Non-GAAP R&Dnon-GAAPFY2026$1.14B – $1.19B–LoweredJul 30, 2026
Non-GAAP R&D Expensenon-GAAPFY2026$1.11B – $1.16B$1.11B – $1.16BLoweredMay 5, 2026
Non-GAAP SG&Anon-GAAPFY2026$1.33B – $1.35B–RaisedJul 30, 2026
Non-GAAP SG&A Expensenon-GAAPFY2026$1.24B – $1.27B$1.24B – $1.27BRaisedMay 5, 2026

Guidance history

Every forecast Neurocrine Biosciences put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Jul 30, 2026GAAP R&DFY2026$1.28B – $1.33BLowered
Jul 30, 2026GAAP SG&AFY2026$1.58B – $1.60BRaised
Jul 30, 2026GAAP Amortization of Acquired Intangible AssetsFY2026$85.00M – $90.00MLowered
Jul 30, 2026Non-GAAP R&DFY2026$1.14B – $1.19BLowered
Jul 30, 2026Non-GAAP SG&AFY2026$1.33B – $1.35BRaised
Jul 30, 2026IPR&DFY2026$23.00MRaised
May 5, 2026GAAP and Non-GAAP IPR&DFY2026$20.00MReaffirmed
May 5, 2026GAAP R&D ExpenseFY2026$1.20B – $1.25BLowered
May 5, 2026GAAP SG&A ExpenseFY2026$1.38B – $1.40BRaised
May 5, 2026Non-GAAP R&D ExpenseFY2026$1.11B – $1.16BLowered
May 5, 2026Non-GAAP SG&A ExpenseFY2026$1.24B – $1.27BRaised
Feb 11, 2026GAAP and Non-GAAP IPR&DFY2026$20.00MNew
Feb 11, 2026GAAP R&D ExpenseFY2026$1.20B – $1.25BNew
Feb 11, 2026GAAP SG&A ExpenseFY2026$1.38B – $1.40BRaised
Feb 11, 2026Non-GAAP R&D ExpenseFY2026$1.11B – $1.16BNew
Feb 11, 2026Non-GAAP SG&A ExpenseFY2026$1.24B – $1.27BRaised
Jul 30, 2025GAAP R&D ExpenseFY2025$960.00M – $1.01BNew
Jul 30, 2025GAAP SG&A ExpenseFY2025$1.14B – $1.16BRaised
Jul 30, 2025Non-GAAP R&D ExpenseFY2025$890.00M – $940.00MNew
Jul 30, 2025Non-GAAP SG&A ExpenseFY2025$980.00M – $1.00BRaised

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Neurocrine Biosciences filed with the SEC as exhibits to Form 8-K or 6-K

  1. Neurocrine Biosciences Reports Second-Quarter 2026
    Results
  2. Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics
    Update
  3. Neurocrine Biosciences Reports First-Quarter 2026
    Results
  4. Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025
    Results
  5. Neurocrine Biosciences Reports Third Quarter 2025 Financial Results
    Results
  6. Neurocrine Biosciences Reports Second Quarter 2025 Financial Results
    Results
  7. Neurocrine Biosciences Reports First Quarter 2025 Financial Results
    Results
  8. Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer
    Update
  9. Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2024 Financial Results
    Results
  10. Neurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator (formerly NBI-1065845/TAK-653)
    Update
  11. Neurocrine Biosciences Announces Commercial Availability of
    News
  12. Neurocrine Biosciences Reports Third Quarter 2024 Financial Results
    Results
  13. Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1117568
    Update
  14. 8-K exhibit EX-99.2
    Update
  15. Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance
    Results